Lantheus Holdings, Inc. (NASDAQ:LNTH) was upgraded by investment analysts at Wells Fargo & Company from a “market perform” rating to an “outperform” rating in a report released on Thursday, November 2nd, Marketbeat.com reports.
A number of other equities analysts have also weighed in on the stock. Jefferies Group LLC restated a “buy” rating and set a $22.00 target price on shares of Lantheus Holdings in a research report on Thursday, October 12th. Zacks Investment Research lowered shares of Lantheus Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, September 20th. BidaskClub lowered shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 17th. Credit Suisse Group increased their price objective on shares of Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Finally, Cantor Fitzgerald began coverage on shares of Lantheus Holdings in a research report on Monday, July 17th. They set an “overweight” rating and a $22.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $24.50.
Shares of Lantheus Holdings (NASDAQ:LNTH) traded up $0.55 during mid-day trading on Thursday, reaching $23.40. 347,334 shares of the company’s stock were exchanged, compared to its average volume of 561,676. The stock has a market capitalization of $845.76 and a PE ratio of 19.95. Lantheus Holdings has a twelve month low of $7.95 and a twelve month high of $24.10. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41.
Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.04. Lantheus Holdings had a net margin of 9.59% and a negative return on equity of 46.45%. The business had revenue of $79.94 million during the quarter, compared to analyst estimates of $77.18 million. During the same period in the prior year, the business posted $0.15 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. sell-side analysts predict that Lantheus Holdings will post 1.02 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Lantheus Holdings, Inc. (NASDAQ:LNTH) Lifted to “Outperform” at Wells Fargo & Company” was first published by BBNS and is the sole property of of BBNS. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://baseballnewssource.com/markets/lantheus-holdings-inc-lnth-upgraded-to-outperform-at-wells-fargo-company/1750917.html.
In related news, Director David F. Burgstahler sold 6,000 shares of Lantheus Holdings stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $17.10, for a total value of $102,600.00. Following the completion of the sale, the director now directly owns 13,248 shares in the company, valued at approximately $226,540.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David F. Burgstahler sold 91,166 shares of Lantheus Holdings stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $17.01, for a total transaction of $1,550,733.66. Following the completion of the sale, the director now owns 13,248 shares of the company’s stock, valued at $225,348.48. The disclosure for this sale can be found here. In the last three months, insiders sold 644,638 shares of company stock worth $11,079,593. Insiders own 2.30% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Thrivent Financial For Lutherans acquired a new stake in Lantheus Holdings during the 2nd quarter valued at approximately $321,000. Royce & Associates LP purchased a new position in shares of Lantheus Holdings during the 2nd quarter valued at approximately $4,896,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Lantheus Holdings during the 2nd quarter valued at approximately $770,000. QS Investors LLC purchased a new position in shares of Lantheus Holdings during the 2nd quarter valued at approximately $2,256,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Lantheus Holdings by 6.3% during the 1st quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock valued at $856,000 after purchasing an additional 4,084 shares in the last quarter. Institutional investors and hedge funds own 89.25% of the company’s stock.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with our FREE daily email newsletter.